Introduction
In response to DNA damage, mammalian cells activate a range of surveillance signalling cascades that ultimately delay cell cycle progression, stimulate DNA repair, and alter the expression of genes essential for the cell's recovery or, in case of irreparable damage, ensure the cell's elimination (Zhou and Elledge, 2000) . A central component of these so-called DNA damage checkpoint pathways in animal cells is the p53 tumour suppressor, a transcription factor which in response to diverse stress stimuli becomes post-translationally modi®ed, stabilized, and competent to induce expression of genes required to halt the cell cycle progression or trigger programmed cell death (Carr, 2000; Vogelstein et al., 2000) . Although activation of p53 is a complex process which requires multiple events whose molecular basis diers somewhat depending on the nature of the activating signal (Giaccia and Kastan, 1998; Meek, 2000) , a key event shared by whichever route is the destabilization of the p53-MDM2 interaction. The MDM2 protein has a dual role in regulation of p53, by blocking p53's transactivation function through physical binding to the N-terminal transactivation domain of p53, and by mediating rapid turnover of the p53 protein by ubiquitination and targeting p53 for degradation by the 26S proteasome (Meek, 2000; Vogelstein et al., 2000) . Recent data indicate that the critical modi®cation which disrupts the p53-MDM2 complex, and leads to stabilization of p53 in response to DNA damaging stimuli such as ionizing radiation, is phosphorylation of serine 20 of p53 (and likely also phosphorylation of MDM2; Chehab et al., 1999) , an event carried out by the Chk2 protein kinase (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) . Chk2 (hCds1) is the human homologue of the Saccharomyces cerevisiae RAD53 and Schizosaccharomyces pombe Cds 1 DNA damage checkpoint-mediating kinases (Zhou and Elledge, 2000) . Upon exposure to genotoxic stress, Chk2 becomes activated by phosphorylation on threonine 68 by the upstream ATM kinase (Melchionna et al., 2000) , and the activated Chk2 then further propagates the signal via diverse DNA damage checkpoint cascades. Apart from the biochemical link between p53 as a physiological substrate of the Chk2 kinase, recent genetic evidence also suggests that these two checkpoint mediators operate in the same pathway. Thus, mutations in the Chk2 gene have been identi®ed in some Li-Fraumeni syndrome patients, in a subset of families who do not harbour mutations in p53, previously shown to predispose to this highly cancerprone condition (Bell et al., 1999) .
While these results are generally consistent with a scenario where Chk2 functions upstream of p53 in a common pathway in response to DNA damage (Carr, 2000; Vogelstein et al., 2000) , precise mechanistic understanding of the link between Chk2 and p53 remains to be elucidated. In addition, while mutations of Chk2 and p53 seem mutually exclusive among the Li-Fraumeni families, apparently concomitant mutations of these two genes, at least in a heterozygous state, have been reported in a sporadic colorectal cancer-derived cell line (Bell et al., 1999) . These unresolved and potentially contradictory results raised the issue of relative growth advantages of cancer cells harbouring single versus simultaneous defects in the emerging Chk2-p53 tumour suppressor pathway. This conceptually important question, along with an attempt to gain further mechanistic insights into the Chk2-p53 interplay, are the subjects of our present study.
Results
Despite the recently demonstrated kinase-substrate relationship between Chk2 and p53 (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) , it remains unclear whether the two proteins form a detectable physical complex in mammalian cells, and to what extent might such potential interaction and/or phosphorylation of p53 by Chk2 be aected by the identi®ed cancer-associated mutations in Chk2 (Bell et al., 1999) . To address these questions, we assessed responsiveness to ionizing radiation (IR) of Myctagged wild-type human Chk2, and a series of Myctagged mutant Chk2 alleles, ectopically expressed in human Saos-2 cells (lacking endogenous p53) transiently reconstituted to express also wild-type p53. The examined parameters encompassed the ability of the dierent versions of Chk2 to become activated in response to IR, to bind the wild-type p53 protein in vivo, and to phosphorylate a GST-p53 fusion protein in an in vitro kinase assay. The three mutant alleles of Chk2 included the engineered catalytically-inactive, dominant-negative D347A mutant (Chehab et al., 2000; Matsuoka et al., 1998) , and the two point missense alleles, R145W and I157T mutated in the putative protein ± protein interaction FHA domain (Durocher et al., 1999) , identi®ed in the HCT-15 colon cancer cell line and as a germ-line mutation in one of the Li-Fraumeni families, respectively (Bell et al., 1999) . As can be seen from the immunoprecipitation data shown in Figure 1a , wild-type Chk2 underwent a mobility shift after exposure to IR (the slower mobility re¯ecting known activatory phosphorylations of Chk2; Matsuoka et al., 1998) , accompanied by an increased capacity to physically interact with the wild-type p53 protein in these cells, and a marked elevation of the immunoprecipitated Chk2 kinase activity towards the GST-p53 substrate. The control, catalytically-inactive Chk2 did not show any sign of mobility shift or activation after IR, though it preserved the basic ability to form the protein ± protein complex with p53, in this case not altered upon IR (Figure 1a, D347A) . In sharp contrast, neither of the two cancer-associated Chk2 mutants were able to bind p53 in vivo, and their in vitro kinase activities remained low even after IR, comparable to the basic activity of wild-type Chk2 seen in non-irradiated cells. Thus, it appears that Chk2 can form a detectable protein ± protein complex with wildtype p53 in vivo, the amount of such complex is elevated upon DNA damage, and the tumour-associated Chk2 mutations render the kinase incapable of such physical interaction with the p53 substrate, regardless of exposure to DNA damage.
The ability of Chk2 to bind wild-type p53 led us to examine whether or not such complex formation occurs also between wild-type Chk2 and the mutant p53 proteins often expressed in high amounts in tumour cells. A series of immunoprecipitation and immunoblotting experiments with Saos-2 cells transiently co-transfected with expression plasmids for wildtype Chk2 and any one of four common cancerassociated mutants of human p53 revealed that the Figure 1 Activation of Chk2 and its physical interaction with p53 after DNA damage. (a) Saos-2 cells were transfected with wild-type p53 and dierent Myc-Chk2 plasmids as indicated, girradiated (10 Gy;+) or left untreated (7). Anti-Myc immunoprecipitates were assayed by immunoblotting to monitor mobility shift of Chk2 (top), co-precipitation of p53 (middle), and Chk2-associated in-vitro kinase activity towards GST-p53 (bottom). Asterisk, a threefold excess of Myc-Chk2-R145W was transfected. The WCE panel indicates overall levels of p53 in corresponding whole-cell lysates, visualized by immunoblotting. (b) Saos-2 cells were transfected with wild-type Myc-Chk2 and dierent p53 plasmids as indicated, g-irradiated (10 Gy), and anti-Myc immunoprecipitates were assayed for co-precipitated p53 (IP: Myc, bottom panel). In parallel, whole cell extracts (WCE) were tested for expression of the dierent p53 versions mutant versions of p53 bound to IR-activated Chk2 in a manner indistinguishable from wild-type p53 ( Figure  1b ). The only p53 mutant which was unable to form a detectable physical complex with Chk2 was the p53 protein defective in its tetramerization domain (Sturzbecher et al., 1992) . These results indicated an intriguing possibility that through their binding to activated Chk2, the overabundant mutant forms of p53 in cancer cells might aect performance of the Chk2 kinase as a checkpoint mediator, an intriguing issue addressed in functional assays with cancer cell lines of dierent p53 and Chk2 status (see below).
To elucidate the complex question of potential additional selective advantage of cancer cells harbouring concomitant defects of both Chk2 and p53 compared with cells in which only one of these two checkpoint regulators is inactive due to a mutation, we chose to study the human colorectal carcinoma cell line HCT-15, previously reported to suer heterozygous mutations in the Chk2 gene (Bell et al., 1999) as well as the p53 gene (O'Connor et al., 1997) . Due to their heterozygous nature, it remained formally possible that the remaining wild-type alleles of either Chk2 or p53, or even both, preserved some residual activity in this cell line, thereby possibly explaining why these two defects occurred in the same tumour cell. To examine whether the wild-type allele of Chk2 was expressed in HCT-15 cells, we performed reverse transcriptase-PCR analysis followed by sequencing of the total cDNA. The results shown in Figure 2a demonstrate that only the mutant form of Chk2, with the C4T change in nucleotide 433 resulting in the Arg to Trp substitution at codon 145 (Bell et al., 1999) , was expressed at detectable levels. This result indicates that the HCT-15 cells lack any wild-type Chk2, and therefore can be regarded as functionally Chk2-de®cient, since the expressed R145W mutant protein is neither activated upon IR, nor is it able to bind to the p53 substrate (see Figure 1a ). In addition, the fact that ectopically expressed Myc-tagged wild-type Chk2, but not the endogenous mutant protein, can still be activated by IR in HCT-15 cells (Figure 2b ) indicates that the upstream regulators of Chk2 in the DNA damage checkpoint are functional.
The demonstration that the HCT-15 cell line lacks functional Chk2 calls also for re-evaluation of the p53 function in these cells, since their previously reported inability to induce expression of the p53-regulated p21, and to impose a G1 arrest after IR (O'Connor et al., 1997), might have re¯ected the inability of the remaining wild-type p53 to become stabilized due to the lack of phosphorylation by Chk2. The theoretical possibility that the wild-type allele of p53 might still be functional in HCT-15 cells seemed also plausible considering the relatively low level of the mutant p53 (P153A) detected by immunoblotting (O'Connor et al., 1997) , potentially allowing some wild-type p53 to escape from any dominant-negative eect of the mutant allele. To unequivocally show whether or not there is any measurable activity of p53 in HCT-15 cells, which might be elevated upon DNA damage, we employed a noninvasive, quantitative luciferase reporter assay previously used to measure E2F-and Mycdependent transcription (Lukas et al., 1997; SantoniRugiu et al., 2000) , adapted here to monitor transactivation of a p53-dependent promoter in living human cells (see Materials and methods section for details). The speci®city of this assay is demonstrated in human U-2-OS cells, wild-type for both p53 and Chk2 (Chehab et al., 2000) , where the activity of the p53-dependent reporter (Mdm2-luc) stimulated after exposure to ionizing radiation, could be entirely blocked by microinjection of the p53-neutralizing antibody DO-1 (Gire and Wynford-Thomas, 1998) but not by control IgG (Figure 3a ). In addition, the fact that the same amount of microinjected DO-1 did not aect luciferase activity driven by a p53-independent reporter plasmid (pGL3-Luc) under identical conditions ( Figure  3a) shows that the assay does not monitor general transcription or even translation activities in these live cells, but rather genuinely re¯ects p53-dependent transactivation. This in vivo assay proved also suitable to detect elevation of p53-dependent transactivation as a consequence of increased expression of wild-type Chk2 in the U-2-OS cells (Figure 3b ), indicating that these tools are appropriate to answer the question about any potential residual activity of p53 in the HCT-15 cell line. Like U-2-OS, the HCT-15 cells also responded to the control pGL3-Luc reporter, while the critical experiment carried out in parallel showed a total lack of any p53-driven reporter activity in irradiated HCT-15 cells, regardless of whether or not ectopic wild-type Chk2 was co-expressed ( Figure 3c ).
Collectively, these data demonstrate that the HCT-15 cells are de®cient in both the p53 and Chk2 functions, and thus argue that at least in some cancer cells, these two defects occur concomitantly, rather than in a strictly mutually exclusive manner as observed among the limited number of the Li-Fraumeni families studied so far (Bell et al., 1999) .
Given the existence of cancer cells harbouring simultaneous aberrations in Chk2 and p53, exempli®ed by the HCT-15 colon cancer cells, we wished to examine whether there might be any potential additional advantage for a cancer cell to be selected for mutation in either Chk2 or p53 in a cellular background already lacking one of these two functions. To test this concept, we chose to monitor the impact of experimental silencing of wild-type Chk2 in the same cellular background (human U-2-OS cells), where the activity of wild-type p53 could be preserved or conditionally neutralized via tetracycline regulatable expression of a dominant-negative allele of p53 (p53DD; Shaulian et al., 1992) . The checkpoint response evaluated in these experiments was the S phase checkpoint activated by IR-induced DNA damage, previously shown to be p53-independent (Xie et al., 1998; Petrini, 2000; Rotman and Shiloh, 1999) , and most recently demonstrated to involve the Chk2 function (Falck et al., 2001) . In preliminary time course experiments measuring DNA synthesis after IR, a similar degree of transient inhibition of DNA replication was detected in U-2-OS cells regardless of the conditional expression of dominant-negative p53, as well as in Saos-2 cells (null for p53), and the extent of DNA inhibition 1 h after irradiation (when the inhibition reached its maximum) was then regarded as a reference 100% value of DNA synthesis inhibition for the subsequent experiments. Response of these three cellular environments modi®ed by ectopic expression of wild-type Chk2 showed slight enhancement of the extent of DNA synthesis inhibition 1 h after exposure to IR, while parallel experiments with cells ectopically expressing the catalytically inactive, dominant-negative Chk2 (D347A) led to signi®cant abrogation of this S phase checkpoint function, demonstrated as a phenomenon known as radioresistant DNA synthesis (RDS; Petrini, 2000; Rotman and Shiloh, 1999) , in all three cell types (Figure 4a ). These results showed that elimination of the Chk2 function seriously undermined the S phase checkpoint response to DNA damage in cells expressing wild-type p53 (U-2-OS cells grown with tetracycline) as well as in cells lacking the p53 function (U-2-OS cells grown without tetracycline, and Saos-2 cells).
Whereas the latter results are consistent with the idea that concomitant defects of Chk2 and p53 might cooperatively disable cellular responses to genotoxic stress, they did not rigorously consider our observation (Figure 1b ) that many if not all mutant p53 proteins commonly found in human malignancies appear capable of binding to activated Chk2. Thus, it remained possible that in cancer cells with overabundant mutant p53, any activated Chk2 might be titrated by such aberrant p53 proteins, thereby also indirectly interfering with checkpoint pathways nor- Figure 3 Monitoring p53 activity and eect of Chk2 in irradiated human cells in vivo. (a) U-2-OS cells were microinjected with the reported plasmids (50 mg/ml; bottom) and puri®ed antibodies (5 mg/ml; top) as indicated. After subsequent 12 h incubation, the cells were exposed to IR (12 Gy), incubated for an additional 2 h, and subjected to noninvasive cell luminescence imaging (see Materials and methods) to measure reporter activity directly in live cells. (b) U-2-OS, and (c) HCT-15 cells were microinjected with the reporter plasmids (50 mg/ml) and the pcDNA3 expression plasmids (100 mg/ml) encoding wild-type Chk2 (Chk2 wt) or no insert as indicated. The injected cells were irradiated and assayed for the in vivo reporter activity by noninvasive luminescence imaging as in (a) mally dependent on Chk2 but independent of p53 function, such as the S phase inhibition upon IR. This possibility was assessed using another regulatable model system, this time allowing overexpression of a common p53 mutant (R248W) in human SKOV ovarian carcinoma cells lacking endogenous p53. As can be seen from immunoblots shown in the insert in Figure 4b , removal of tetracycline from the growth medium resulted in accumulation of the mutant p53 in such cells, to a degree comparable with, or even slightly exceeding, the level of this mutant detected as endogenous protein in the BT-549 breast cancer cell line (Bartek et al., 1990) . Comparative time-course experiments monitoring DNA synthesis following IR then revealed that the presence of overabundant p53R248W, which binds Chk2 (Figure 1b) , moderately delayed the onset of the S phase checkpoint during the initial 20 min or so after irradiation, yet it did not signi®cantly aect the overall response and the degree of DNA synthesis inhibition during the later stages including the maximum inhibition achieved by 1 h after exposure to IR (Figure 4b ). These results suggest that despite a moderate eect of overabundant, cancerassociated mutant p53 proteins via their potential titration of activated Chk2, the checkpoint responses which normally operate independently of p53 are implemented even in such p53-mutant cancer cells (Figure 4b ), while concomitant defects in both Chk2 and p53 cooperate to prevent cellular checkpoint responses to DNA damage.
Discussion
Available evidence for Chk2 as an upstream regulator of p53 in a linear pathway activated in response to DNA damage encompasses the ability of Chk2 to phosphorylate p53 in a DNA damage-dependent and ATM-dependent manner, defective phosphorylation and action of p53 in mouse ES cells genetically deprived of Chk2 (Chehab et al., 2000; Hirao et al., 2000; Shieh et al., 2000) , and occurrence of germ-line mutations of Chk2 and p53 in non-overlapping subsets of Li-Fraumeni families predisposed to a similarly wide spectrum of tumours in either case (Bell et al., 1999) . Our present data support and extend such an emerging intimate relationship between these two tumour suppressors by demonstrating that the Chk2 and p53 proteins form a physical complex in human cells, that the amounts of such complexes increase upon exposure to IR, and that the formation of this complex requires an intact FHA domain of Chk2, and the tetramerization domain of p53. The latter conclusion is also consistent with the tetramerization-de®cient p53 mutant being a poor substrate of Chk2 in vitro (Shieh et al., 2000) . On the other hand, the activatory phosphorylation of Chk2 itself appears neither entirely necessary nor sucient for binding to p53 in vivo, as shown by the preserved interaction of p53 with the catalytically inactive, non-activatable Chk2, and the lack of binding to p53 by the I157T mutant of Chk2 which was able to undergo the activatory mobility shift upon IR, respectively (see Figure 1a) .
Both p53 and Chk2 are important components of the DNA integrity checkpoints and it is therefore not surprising that either of them is targeted by inactivating mutations associated with both hereditary and sporadic cancers (Bell et al., 1999; Haruki et al., 2000; Vogelstein et al., 2000) . It is more unexpected, however, to ®nd the p53 and Chk2 functions abrogated concomitantly, as exempli®ed here by the HCT-15 colon cancer cell line. The lack of Chk2 function in HCT-15 cells is supported by the selective expression of only the mutant allele (see Figure 2a) , and the (7Tet) to express dominant negative p53 or not (+Tet), compared with Saos-2 cells (p53-null), 1 h after exposure to IR (10 Gy). (b) DNA synthesis in g-irradiated (10 Gy) SKOV-derived p53 ± 248 cells induced (7Tet) to express p53-R248W or not (+Tet), at the indicated time points after irradiation. Insert, levels of the p53 mutant R248W in p53-248 and BT549 cells (BT). Cdk7, loading control de®ciency of Chk2-dependent degradation of Cdc25A and restoration of this S phase checkpoint response by ectopic wild-type Chk2 in this cell line (Falck et al., 2001) . The inability to activate p53 function by DNA damage even upon reconstitution of wild-type Chk2 (this study) demonstrates the absence of any functional p53 in HCT-15. The luciferase live-cell imaging reporter assay for measuring p53 activity, developed and used here for the ®rst time, should prove useful for many dynamic studies to correlate activity of p53 to any other parameters which can be followed in a noninvasive manner, including response to diverse types of stress in single cells. The assay is highly sensitive, quantitative, and allows p53-regulated gene expression to be followed repeatedly in the same cells in real time.
Conceptually the most signi®cant issue addressed here is the apparent discrepancy between the emerging linear Chk2-p53 pathway and the somewhat counterintuitive occurrence of simultaneous defects in these two genes in HCT-15 cells. This question was also closely related to the potential entrapment of activated Chk2 into futile p53 complexes in cells harbouring overabundant missense-mutated p53 proteins, an intriguing possibility which emerged from our present analysis of Chk2-p53 interaction. We believe our data obtained using model cell lines with regulatable Chk2 and p53 and their S phase checkpoint response to IR can reconcile these issues. The most compelling result in this regard is the present evidence that the extent of the S phase checkpoint response to DNA damage (Xie et al., 1998; Petrini, 2000; Rotman and Shiloh, 1999; Falck et al., 2001) was not altered regardless of whether the cells expressed wild-type, mutant, or no p53, and that neutralization of Chk2 function even in such tumour cells with deleted or mutant p53 abrogated the S phase checkpoint (see Figure 4) . This result shows one speci®c example of a DNA integrity checkpoint whose performance is not seriously undermined by loss of p53 function, and which becomes deregulated upon subsequent silencing of Chk2 in a p53-null or p53-mutant background. Considering the widely held view that abrogation of cell cycle checkpoints contributes to genomic instability and thus to tumour progression (Albrechtsen et al., 1999; Vogelstein et al., 2000; Carr, 2000) our data lend support to the notion that mutations of Chk2 can provide some additional selective advantage even to cells with deleted or mutant p53. Although not directly examined here, the reverse temporal order of such mutations, namely silencing the p53 function in cells already mutant for Chk2, would be expected to provide several analogous scenarios in which subsequent mutation in p53 should enhance genomic instability and/or allow survival of damaged cells due to loss of the pro-apoptotic function of p53 (Vogelstein et al., 2000; Carr, 2000) . The obvious examples would be p53-dependent checkpoint responses to DNA damaging agents such as UV light which preferentially activate Chk1 rather than Chk2 Caspari, 2000) , or stimuli such as mitogenic overload which activate p53 via the p14ARF, rather than the Chk2 cascade (Sherr, 1998) . The key point of this concept is the existence of multiple safeguard pathways in mammalian cells, only a subset of which relies on phosphorylation of p53 by Chk2, while other defence mechanisms involve selectively p53 or Chk2, but not the other. Due to their fundamental roles in this network of cascades responding to genotoxic stress, mutations in p53 or Chk2 genes become selected for during tumorigenesis. There is most likely a lower selection pressure to target p53 and Chk2 concomitantly in the same tumour cell, such as in the HCT-15 colon cancer cell line (Bell et al., 1999; O'Connor et al., 1997) . Such cases of dual defects in the Chk2-p53 tumour suppressor pathway might be explained by the existence of non-overlapping checkpoint pathways that require only p53 or only Chk2, and whose inactivation through the secondary mutations may provide sucient additional advantage to be preserved and selected for during the clonal evolution of a subset of malignancies.
Materials and methods

Antibodies and immunochemical methods
Mouse monoclonal antibodies to p53 (DO-1), Cdk7 (MO-1), and Chk2 (DCS-270), as well as immunoblotting, immunoprecipitation, and in vitro kinase assays were described (Falck et al., 2001; Santoni-Rugiu et al., 2000) . Rabbit antisera to p53 (FL-393) and mouse monoclonal antibody to CD20 were purchased from Santa Cruz and Becton Dickinson, respectively. 9E10 antibody to Myc epitope was a gift from G Evan.
Plasmids
To construct the Myc-tagged Chk2 expression vector, the human Chk2 cDNA (gift from S Elledge) was ampli®ed by PCR with Pfu polymerase (Stratagene) and cloned into a pcDNA3 vector (Invitrogen) containing a Myc tag. The catalytically inactive D347A, and tumour-associated R145W, and I157T mutants of Chk2 were generated using the QuickChange Site-Directed Mutagenesis kit (Stratagene). Expression vectors encoding wild-type p53 and dierent tumour-derived p53 mutants were a gift from B Vogelstein, John Hopkins University, USA. The oligomerization defective (OD) p53 expression vector 1262 was kindly provided by J Jenkins. Puri®cation of the GST-p53 fusion protein was performed as described (Selivanova et al., 1996) . The p53-dependent reporter plasmid (Mdm2-Luc) was a gift from Moshe Oren, and the pGL3 control vector plasmid (pGL3-Luc) was supplied by Promega.
Cell culture
Human osteosarcoma U-2-OS and Saos-2, and the breast carcinoma BT-549 cells were grown in DMEM containing 10% foetal bovine serum (FBS). HCT-15 cells were grown in RPMI 1640 medium containing 10% FBS. The SKOVderived p53 ± 248 clone conditionally expressing the p53-R248W mutant (gift from P Chumakov), and the U-2-OSderived p53DD clone conditionally expressing dominant negative version of p53 were grown in DMEM containing 10% FBS and 1 mg/ml tetracycline. Expression of the transgene was induced by culturing the cells in tetracyclinefree growth medium for 24 h. Isolation of CD20-positive U-2-OS/p53DD and Saos-2 cells with anti-CD20 coupled Dynabeads was described (Santoni-Rugiu et al., 2000) . Transgenes were delivered by standard calcium phosphate transfection or electroporation. Ionizing radiation was delivered by X-ray generator (RT100, Philips Medico; 100 kV, 8 mA, dose-rate 0.92 Gy/min) and cell extracts prepared 1 h later except where indicated otherwise.
Radioresistant DNA synthesis assay
Inhibition of DNA synthesis after ionizing radiation was monitored as described (Lim et al., 2000) . Cells were labelled for 24 h with 20 nCi/ml 14 C-thymidine, followed by another 24 h-incubation in non-radioactive medium. Cells were then irradiated with either 0 Gy (control) or 10 Gy and [ 3 H]thymidine (2.5 mCi/ml) was added at the indicated time points. After 15 min, cells were harvested in 0.25 M NaOH, either directly or after isolation with anti-CD20-coupled Dynabeads (Figure 4a ), and radioactivity measured in a liquid scintillation counter. The DNA synthesis was estimated by the ratios of [ 
Sequencing of cDNA
Isolation of total RNA and cDNA synthesis was described (Santoni-Rugiu et al., 2000) . A fragment encompassing the ®rst 300 amino acids of Chk2 was ampli®ed by PCR using the following primers: 5'-ATGTCTCGGGAGTCGGATG-TTG-3', and 5'-CTCTCCCCCTTCCATCAATTCC-3'. The corresponding PCR product was isolated and sequenced with the following primer: 5'-TGTGTGAATGACAACTACTGG-3', using the Thermo Sequenase radiolabelled terminator cycle sequencing kit (Amersham).
Noninvasive cell luminescence imaging
Cell nuclei were microinjected with p53-dependent reporter plasmid (Mdm2-Luc) or control reporter plasmid (pGL3-Luc) together with pcDNA3-Myc-Chk2 or empty pcDNA3-Myc expression plasmids using Zeiss Automatic Microinjection System in combinations and concentrations speci®ed in the legend to Figure 3 . Where indicated, anity-puri®ed antip53-neutralizing antibody (DO-1) or control mouse nonimmune immunoglobulin (Sigma) were co-injected. Twelve hours later, the cells were exposed to a single pulse of ionizing radiation (10 Gy) and incubated for an additional 2 h. Luminescence produced by live cells was measured using the Zeiss Axiovert 135 M microscope equipped with a Fluar 106objective and an interactive photon estimation system (cooled ultrasensitive ICCD-576-S/RB EM detector operated by a ST-138S controller; Princeton Instruments) allowing discrimination of single photon events. Brie¯y, the cells were placed on a heated microscope stage (378C), the regions containing the productively injected cells were found using coordinates on grid coverslips (Eppendorf), and the medium was supplied with 1 mM beetle luciferin (Promega). Immediately after addition of luciferin, the emitted photoelectrons were acquired in complete darkness. The total acquisition time was 5 min per ®eld containing 20 ± 30 productively injected cells. Quantitation of the luminescence images was performed after dark charge subtraction and corrections of distortions across the ®eld using the photon estimation software package provided by the manufacturer. The viability of the microinjected cells was assessed by subsequent immunostaining of the microinjection marker (non-immune rabbit IgG; 1 mg/ml needle concentration). Expression of the Myc-tagged Chk2 protein in the productively microinjected cells was veri®ed by immunostaining with anti-Myc antibody (9E10). The data represent combined results from at least three independent experiments for each combination of the microinjected plasmids.
